Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

A new study suggests that popular weight loss drugs may reduce the risk of suicide in adolescents. KYW medical editor Dr. Brian McDonough has more.

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The medication’s primary mechanism involves mimicking glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the ...

A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...